Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial
Johann S. de Bono(Royal Marsden Hospital), Niven Mehra(Radboud University Nijmegen), Giorgio V. Scagliotti(Ospedale San Luigi Gonzaga), Elena Castro(Instituto de Investigación Biomédica de Málaga), Tanya B. Dorff(City of Hope), Adam Stirling(Cancer Council Queensland), Arnulf Stenzl(University Children's Hospital Tübingen), Mark T. Fleming(Virginia Oncology Associates), Celestia S. Higano(University of Washington), Fred Saad(Centre Hospitalier de l’Université de Montréal), Consuelo Buttigliero(University of Turin), Inge M. van Oort(Radboud University Medical Center), Alexander Laird(Pfizer (United States)), Marielena Mata(Pfizer (United States)), Hsiang-Chun Chen(Pfizer (United States)), Cynthia G. Healy(Pfizer (United States)), Akos Czibere(Pfizer (United States)), Karim Fizazi(Institut Gustave Roussy)
Cited by 276Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis